Current findings from the phase 1/2 CaDAnCe-101 trial show no predictive factors of improved responses with BGB-16673 in patients with CLL or SLL.
Lydia Scarfò, MD
Advertisement
Articles by Lydia Scarfò, MD
Advertisement
Latest Updated Articles
Novel BTK Degrader Shows Activity in CLL/SLL Regardless of Mutation StatusPublished: June 21st 2025 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Lurbinectedin/Atezolizumab Maintenance in ES-SCLC
2
Which Therapy Has the Best Efficacy in Transplant-Ineligible NDMM?
3
Tarlatamab May Offer New SOC for Relapsed ES-SCLC With Brain Metastases
4
Companion Diagnostic Earns FDA Approval for Imlunestrant in Breast Cancer
5
